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Since unexpected sudden deaths have been reported with the use of diverse non-cardiac
drugs, cardio-safety experts focused their attention on security measures to improve sur-
vival rates in heart stoppages due to this prescribed drugs (Inchauspe, 2010a). Considering
that prolongation of the QTc is a reliable marker of a menacing arrhythmia called torsade
de pointes (TdP) – that can progress to ventricular ﬁbrillation, application of Bazett, or
Rautaharhu formulas can lead to a proper predictive valuation of a “torsadogenic risk.”
Case-analysis raises up the proposal that QTc or QTp will allow to identify high risk
groups; performs a close pharmaco-vigilance and legally register ECG follow-up, avoiding
unnecessary withdrawal of useful drugs from market.
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INTRODUCTION
Sudden unexpected deaths from heart arrest have been reported
with use of non-cardiac drugs since the early 1960s (Iyer, 2010).
These drugs, which cause sudden death, have centered on torsade
de pointes (TdP), a polymorphic ventricular arrhythmia that can
progress to ventricular ﬁbrillation and sudden death. Prolonga-
tion of the QTc interval is a surrogate marker for the ability of a
drug to cause TdP. In individual patients an absolute QTc inter-
val of >500 ms or an increase of 60 ms from baseline is regarded
as indicating an increased risk of TdP. However, TdP can occur
with lower QTc values or changes. Concern about a relationship
between QTc prolongation, TdP, and sudden death applies to a
wide range of drugs and has led to the withdrawal or restricted
labeling of several. Arrhythmias are more likely to occur if drug-
induced QTc prolongation coexists with other risk factors, such
as individual susceptibility, presence of congenital long QT syn-
dromes, heart failure, bradycardia, electrolyte imbalance, overdose
of a QTc-prolonging drug, female sex, restraint, old age, hepatic or
renal impairment, and slow metabolic status. Pharmacodynamic
and pharmaco-kinetic interactions can also increase the risk of
arrhythmias. The risk should be viewed in the context of the overall
risks and beneﬁts of anticancer treatment. It seems prudent,where
possible, to select anticancer treatments that are not associated
with marked QTc prolongation. If use of a QTc-prolonging drug
is warranted, then measures to reduce the risk should be adopted.
l-Asparaginase is marketed as a drug for the treatment of acute
lymphoblastic leukemiaThemain side effect is an allergic orhyper-
sensitivity reaction; anaphylaxis is a possibility. No cardiac arrest
effect has been observed before. However, in our clinical practice,
a heart arrest was observed in a 1-year-old infant with leukemia.
EXAMPLE CASE
A male 1-year-old infant with Lymphatic acute leukemia was
admitted in Hospital de Niños “Sor Maria Ludovica,” in La Plata,
Buenos Aires, Argentina. He received the following treatment:
Therapeutic protocol: IB protocol, MARMA Interfant-05
– Vincristine: 0.6 mg (push)
– Daunorubicin: 12 mg/kg
– l-Asparaginase: 1000 UI.
Particularly, after intravenously administering l-Asparaginase at
the Hematology Ward, at 12:30 h the patient suffered cardiorespi-
ratory arrest. Basic and advanced CPR techniques were initiated –
endotracheal intubation and ambu ventilation, plus two doses of
adrenaline and continued until the patient entered the Critical
Care Unit about half an hour later. He presented hemodynamic
decompensation (Table 1), hypothermia, and poor peripheral
perfusion.
MATERIALS AND METHODS
Before a suspected diagnosis of an ANAPHYLACTIC OR IDIOS-
INCRATIC REACTION for this cardiac arrest, the child was
treated as follows:
Basic and Advanced CPR (ILCOR) protocol
– Adrenaline (two doses).
Endotracheal intubation: respiratory Mechanical Assistance
(RMA)
Setting: 1/fr= 22/VT 90/0.7 ri
VCV Mode: I:E= 1: 2.8.
Intravenous medications:
– H.P.: 60/2/1
– Colloid expansion: 10 mg/Kg
– Fentanyl: 1 gamma/kg/h
– Midazolam: 0.1 mg/kg/h
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– Dopamine: 10 gamma/kg/min.
Hematological treatment:
K vitamin: 5 mg/dose/day.
After indicating the inotropic support and the volemia expansion
by means of crystalloids, laboratory results were received. They
conﬁrmed hemostasis alteration, which is corrected by providing
K vitamin (see Table 2).
RESULTS
Fortunately, this kid had a favorable evolution, as we can see in his
tests controls (see Table 3).
In Figure 1, an ECG sample performed a day after the emer-
gency is shown. It features a frequency of almost 200/min and P
wave absence (only catching the last four beats), most presumably
due to an inotropic effect.
Cardiac toxicity from these drugs is reported in Goodman–
Gilman´s Treatise.
Individual idiosyncratic potential risk increases this danger in
the whole of the protocol products (Litchner, 2010). Among them,
both Vincristine and l-Asparaginase cause severe hepatotoxicity,
Table 1 | Parameters I: hemodynamic decompensation.
Cardiac frequency 160/min
T.A. 48/32mmHg
O2 sat. 100%
T ˚ 36˚C (hypothermia – coldness in distal extremities)
Peripheral perfusion Capillary repletion>3 s
Photomotor reﬂex Isocoria – reactive pupillary reﬂex
Table 2 | Parameters II: hemostase impairment.
Prothrombin conc. 52%
KPTT 18.4 s
Partial thromboplastin time 86 s
Table 3 | Parameters III: recovery.
Cardiac rate 140/min
T.A. 82/55mmHg
O2 sat. 100%
Respiratory rate 22/min
Peripheral pulses Present
derived from their pharmaco-kinetic metabolism, as was shown
in the hemostasis defect.
The new decision of spreading the infusions of the protocol
drugs within the week was made in order to allow the liver to
recover (Swedborg, 2010).
The condition regressed completely at night (around 9:00 pm),
and control parameters came back to normal (see Table 2).
DISCUSSION
Currently, there are many products that can induce QT-interval
prolongation at the ECG, thus favoring sudden death (Inchauspe,
2010b).
WHO deﬁnes Sudden Death as an episode appearing within
24 h of the beginning of an illness.
Under both eastern and western concepts, the combinations
proposed in some protocols (and others enlisted by Dr. Wang
(Wang, 2010) in the Harvard Ofﬁce of Toxicology Exploration)
could lead to a disruption of the ionic potassium channels of the
myocardial cells (Asai, 2010),mostly in patients with congenital or
acquired Long QT Syndrome. This condition could give rise to the
appearance of precocious post-depolarizations (PDPs). Once they
have reached a threshold amplitude, the PDPs can trigger highly
risky arrhythmia known as “Torsade de pointes” (Dessertenne,
1966; Dessertenne et al., 1966), and a possible cardiac arrest.
Fortunately, today there is the possibility of carrying out ambu-
latory studies of cardiac frequency variability through continuous
monitoring of spectral analysis of R–R′ (Inchauspe, 2011), cor-
rected QT formulas are still a very practical way to determine
QT-interval length next to the patient’s bed:
Application of QTc (corrected) Bazett Formula:
QT(c) = QT√
R − R′
or QTp (precision) Rautaharhu Formula:
QT(p) = 656
1 + cardiac rate
100
Both formulas are appropriate as a QT screening since val-
ues over 0.45 s will be indicative of a QT-interval prolongation.
And rates over 0.66 s would be likely to pose a torsadogenic risk
(Lanzotti and Citta, 2003).
Proposal of a QTc or QTp screening will allow us to:
(a) Identify high risk groups;
(b) Perform close pharmaco-vigilance during treatment;
FIGURE 1 | ECG sample performed 24 hours after the emergency.
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(c) Legally register ECG follow-up (useful as medical responsibil-
ity evidence);
(d) Avoid the unnecessary withdrawal of essential drugs from the
market.
Each year 1,500,000 patients severely injured by prescribed drugs
require hospitalization.
Out of these, 100,000 die, this being the fourth cause of death
in USA.
Careful, long-term evaluation of cardiovascular safety can lead
to better medical treatments.
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